Below is a list of current clinical trials open to enrollment at New England Cancer Specialists. Trials can open and close very quickly, depending on the phase of the study, responses from patients already enrolled, or FDA requests.
We try to have a trial available in every disease area, but this isn’t always possible. If you don’t see a study that might be right for you, please ask your doctor or nurse.
For a full list of clinical trials across the U.S., visit ClinicalTrials.gov.
If you have questions or wish to speak with someone from our research department, contact us.
T-1-23 | VOLGA
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA) Learn More
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) Learn More
CB-3-23 | CAMBRIA-1
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) Learn More
CB-2-23 | ASCENT-05
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) Learn More
CB-1-23 | evERA Breast Cancer
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) Learn More
CB-4-23 | ELEVATE
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE) Learn More
The CompassHER2 Trials: CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Trial of T-DM1 Compared with T-DM1 and Tucatinib
Breast, CB-3-21 (MK3475-B49)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy vs. Placebo Plus Chemotherapy for the Treatment of Chemotherapy Candidate HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer Keynote B49
Breast, N-1-21 (WO42633)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy ASTEFANIA
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer Learn more
Genomics, EAY131 (MATCH)
Molecular Analysis for Therapy Choice. Learn more
TAPUR: Targeted Agent and Profiling Utilization Registry Study
Lung, (T-4-20) TH-138 A Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked Learn more
HARMONi | T-3-23
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of Ivonescimab (SMT112 or AK112) or Placebo Plus Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi) Learn More
Melanoma, EA6141 A Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma Learn more
Multiple Myeloma, JPW-1-21 (MM 19-291)
A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
For more information on these clinical trials, visit (log-in required): NECS Clinical Trials